Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.65 |
| ▸ | CTSS | P25774 | 10/20 | 0.65 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7424230 | 1.00 | CTSK (0.65) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL8140278 | 0.86 | CTSK (0.67) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL16255614 | 0.86 | CTSK (0.65) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL30660249 | 0.86 | CTSK (0.65) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL3686092 | 0.86 | CTSK (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL24815320 | 0.86 | CTSK (0.65) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL3684502 | 0.84 | CTSS (0.49) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL245261 | 0.84 | CTSK (0.68) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL10076128 | 0.84 | CTSK (0.63) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL8239753 | 0.84 | CTSS (0.72) | CTSKCTSSCTSLCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | NAUREX, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | KHAN AMIN (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | GLS, HGFAC, AADAC | CTSK 251/4885CTSS 416/4885CTSL 426/4885 |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | GLS, HGFAC, AADAC | CTSK 251/4885CTSS 416/4885CTSL 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.